Literature DB >> 22488023

Patient-centered management of chemotherapy-induced nausea and vomiting.

Steven Grunberg1.   

Abstract

BACKGROUND: Oncology providers frequently underestimate the incidence of chemotherapy-induced nausea and vomiting (CINV), and patients often are reluctant to report symptoms. Inadequate patient-provider communication is a significant barrier to optimal management of this debilitating toxicity.
METHODS: The author reviews relevant published data and methods to optimize the clinical care of patients receiving chemotherapy with moderate-to-high emetogenic potential.
RESULTS: Patient reticence plus physician expectations that patients will report symptoms accurately lead to lapses in communication and suboptimal clinical care.
CONCLUSIONS: Communication strategies should serve to encourage patients to share the responsibility for establishing goals of therapy and understanding the risks and benefits of their selected antiemetic regimen, thereby becoming active participants in their own cancer care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488023     DOI: 10.1177/107327481201902s03

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  4 in total

1.  Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.

Authors:  Sonja Koch; Axel Wein; Jürgen Siebler; Frank Boxberger; Markus F Neurath; Hanns-Detlev Harich; Werner Hohenberger; Frank Dörje
Journal:  Support Care Cancer       Date:  2013-04-09       Impact factor: 3.603

Review 2.  Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel.

Authors:  Giampaolo Bianchini; Grazia Arpino; Laura Biganzoli; Sara Lonardi; Fabio Puglisi; Daniele Santini; Matteo Lambertini; Giovanni Pappagallo
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

3.  Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey.

Authors:  Cheryl Vidall; Paz Fernández-Ortega; Diego Cortinovis; Patrick Jahn; Bharat Amlani; Florian Scotté
Journal:  Support Care Cancer       Date:  2015-05-08       Impact factor: 3.603

4.  Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.

Authors:  Kaoru Kubota; Mitsue Saito; Kenjiro Aogi; Ikuo Sekine; Hirohisa Yoshizawa; Yasuhiro Yanagita; Hiroshi Sakai; Kenichi Inoue; Chiyoe Kitagawa; Takashi Ogura
Journal:  Support Care Cancer       Date:  2016-04-29       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.